USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: SYNZYME TECHNOLOGY, INC.
City: IRVINE
State: CA
Zip+4: 92618-
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,897,224.00 14
SBIR Phase II $6,344,565.00 3

Award List:

Nitroxide Labeled Hemoglobin as a Blood Substitute

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Carleton Hsia
Award Amount: $98,400.00
Abstract:
A number of biopharmaceutical companies have successfully taken hemoglobin-based oxygen carriers (Hinto phase I clinical trial. However, transfusions have been limited to low dosage levels due to obsvasoconstrictive effects at high dosage levels in pre-clinical animal studies. This proposal deals… More

EYNZYMES IN HEART

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $100,000.00

NITROXIDE IN BRAIN TUMOR RADIOTHERAPY

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $100,000.00

NEUROPROTECTIVE REPERFUSION THERAPY WITH PNA

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hsia, carleton j
Award Amount: $100,000.00

PNA, NITROXIDE AND 60HDA FOR METASTATIC NEUROBLASTOMA

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hsia, Carleton J
Award Amount: $100,000.00

PNA for Stroke

Award Year / Program / Phase: 1998 / SBIR / Phase II
Agency: HHS
Principal Investigator: Hsia, carleton j
Award Amount: $515,032.00

PND (POLYNITROXYL-DEXTRAN): GUT PROTECTION AFTER SHOCK

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Carleton J. Hsia
Award Amount: $100,000.00
Abstract:
Not Available The subject program seeks to design, develop, and fabricate a miniature actuation and control system suitable for the control of pinnate position on a tactical solid rocket motor (SRM). Next-generation missile systems must be versatile, agile, and smart. IN SRM's this smart… More

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Carleton J. Hsia
Award Amount: $100,000.00
Abstract:
Not Available Aspen Systems proposes to develop new Ultra-High Temperature Resistant Aerogels that will withstand temperatures as high as 2300 K for long periods of time. The new insulation will be based Hafnium and Zirconium carbides. Refractory hafnium and zirconium

POLYNITROXYL HEMOGLOBIN:NEUROPROTECTIVE OXYGEN CARRIER

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Carleton J. Hsia
Award Amount: $100,044.00
Abstract:
DESCRIPTION: (Investigator's abstract) Polynitroxyl hemoglobin (PNH) will be developed as a neuroprotective oxygen carrier. PNH is different from 1st generation hemoglobin-based oxygen carriers (HBOCs) in that it has added anti-inflammatory activity in addition to… More

NITROXIDE THERAPY FOR INFLAMMATORY BOWEL DISEASE

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Carleton J. Hsia
Award Amount: $100,000.00
Abstract:
DESCRIPTION (Adapted from the application): Free radicals play important roles in inflammatory bowel disease (IBD), and the reduction or elimination of the adverse effects of these oxidants could provide novel therapies. Antioxidants have been reported to reduce tissue injury in… More

TOPS-ESTER MODULATION OF UVB-INDUCED IMMUNE SUPPRESSION

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Carleton J. Hsia
Award Amount: $98,736.00
Abstract:
DESCRIPTION (provided by applicant): A TOPS-ester, diethyl 2,2,6,6-tetramethyl-1-oxyl-4-piperidene succinate (DETOPS), is a topical drug selected for development for its unique ability to compartmentalize within skin cells and express antioxidant activity that limits oxidant mediated pathologies… More

TOPS-Ester: Pharmacokinetics and Imaging in Human Skin

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Carleton J. Hsia
Award Amount: $100,003.00
Abstract:
DESCRIPTION (provided by applicant): TOPS-ester is a topical drug selected for development for it's unique ability to compartmentalize within skin cells and express antioxidant activity that limits oxidant mediated pathologies including psoriasis, sunburn, skin aging and skin cancer. The objective… More

Brain Injury During CPR Prevented by Vascular Nitroxide

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Carleton J. Hsia
Award Amount: $100,004.00
Abstract:
DESCRIPTION (provided by applicant): The brain damage that frequently accompanies cardiac arrest and resuscitation is devastating. Fewer than 10% of cardiopulmonary resuscitation (CPR) attempts result in survival without brain damage when treatment occurs in pre-hospital or a non-special care… More

PNA for Stroke

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: Carleton J. Hsia
Award Amount: $2,928,858.00
Abstract:
DESCRIPTION (provided by applicant): Stroke is the 3rd leading cause of death in the U.S. and is also a leading cause of severe, long-term disability. The total cost of stroke to the United States is estimated at about $43 billion per year. The only FDA-approved treatment for acute ischemic stroke… More

STROMA-FREE HEMOGLOBIN and HBOC PRODUCTION

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $100,037.00

Polynitroxylated Pegylated Hemoglobin for Traumatic Brian Injury Resuscitation

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Carleton Hsia – 949-453-1072
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): Traumatic brain injury (TBI) is a leading cause of morbidity and mortality especially when complicated by secondary insults such as hypotension. Vulnerability of TBI patients to hypotension is well recognized and identifies a key need for new approaches. The goal… More

Polynitroxylated Pegylated Hemoglobin for Traumatic Brian Injury Resuscitation

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Carleton Hsia – 949-453-1072
Award Amount: $2,900,675.00
Abstract:
DESCRIPTION (provided by applicant): Traumatic brain injury (TBI) is a leading cause of morbidity and mortality especially when complicated by secondary insults such as hypotension. Vulnerability of TBI patients to hypotension is well recognized and identifies a key need for new approaches. The goal… More